# Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

> **NCT03865407** · PHASE2 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 17 (actual)

## Conditions studied

- Hyperuricemia
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT03865407
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-10
- **Primary completion:** 2020-10-07
- **Final completion:** 2020-10-07
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** inability to achieve recruitment goals at a single center and given the current pandemic conditions
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03865407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03865407, "Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03865407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*